More than 3 million U.S. adults live with inflammatory bowel disease (IBD), a medical condition encompassing Crohn’s disease and ulcerative colitis. These sometimes painful conditions are characterized by persistent inflammation in the gastrointestinal tract (GI), leading to potential GI damage.
Humira (adalimumab) is one biologic drug that has proven effective in alleviating symptoms of IBD and other autoimmune disorders. However, its cost can be exorbitant, reaching thousands of dollars when paid out-of-pocket. Although most health insurance generally includes coverage for Humira, the extent of coverage can vary depending on the individual plan.
